Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort

References

• Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362(14):1312–1324. doi:10.1056/NEJMra0912522
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218. doi:10.1097/01.ASN.0000133041.27682.A2
   PubMed Web of Science ®Google Scholar
• Sprague SM, Marcuccilli M, Rakov V. Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease. Clin Investig (Lond). 2015;5(1):9–21. doi:10.4155/CLI.14.110
   Google Scholar
• Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193–205. doi:10.2147/IJNRD.S35632
   PubMedGoogle Scholar
• Ketteler M, Wüthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease—challenges and solutions. Clin Kidney J. 2013;6(2):128–136. doi:10.1093/ckj/sfs173
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 suppl 3):S1–S201.
   PubMed Web of Science ®Google Scholar
• Greig SL, Plosker GL. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. Drugs. 2015;75(5):533–542. doi:10.1007/s40265-015-0366-1
   PubMed Web of Science ®Google Scholar
• Fissell RB, Karaboyas A, Bieber BA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int. 2016;20(1):38–49. doi:10.1111/hdi.12315
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017;32(11):1918–1926. doi:10.1093/ndt/gfw460
   PubMed Web of Science ®Google Scholar
• Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl. 2004;66(90):S25–S32. doi:10.1111/j.1523-1755.2004.09005.x
   Web of Science ®Google Scholar
• Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697–703. doi:10.2215/CJN.00560206
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al. PA21 Study Group. A Phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638–647. doi:10.1038/ki.2014.58
   PubMed Web of Science ®Google Scholar
• Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(8):59–67. doi:10.5414/CN109021
   PubMed Web of Science ®Google Scholar
• Kendrick J, Parameswaran V, Ficociello LH, et al. One-year historical cohort study of the phosphate binder sucroferric oxyhydroxide in patients on maintenance hemodialysis. J Ren Nutr. 2019;29(5):428–437. doi:10.1053/j.jrn.2018.11.002
   PubMed Web of Science ®Google Scholar
• Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant. 2000;15(11):1841–1846. doi:10.1093/ndt/15.11.1841
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int. 2009;76(suppl113):S1–S130.
   Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1–59. doi:10.1016/j.kisu.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Floege J, Covic AC, Ketteler M, et al.; Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037–1046. doi:10.1093/ndt/gfv006
   PubMed Web of Science ®Google Scholar
• Bock F, Stewart TG, Robinson-Cohen C, et al. Racial disparities in end-stage renal disease in a high-risk population: the Southern Community Cohort Study. BMC Nephrol. 2019;20(1):308. doi:10.1186/s12882-019-1502-z
   PubMed Web of Science ®Google Scholar
• Norris KC, Williams SF, Rhee CM, et al. Hemodialysis disparities in African Americans: the deeply integrated concept of race in the social fabric of our society. Semin Dial. 2017;30(3):213–223. doi:10.1111/sdi.12589
   PubMed Web of Science ®Google Scholar
• Norton JM, Moxey-Mims MM, Eggers PW, et al. Social determinants of racial disparities in CKD. J Am Soc Nephrol. 2016;27(9):2576–2595. doi:10.1681/ASN.2016010027
   PubMed Web of Science ®Google Scholar
• Newsome BB, Kilpatrick RD, Liu J, et al. Racial differences in clinical use of cinacalcet in a large population of hemodialysis patients. Am J Nephrol. 2013;38(2):104–114. doi:10.1159/000353298
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Parekh RS, Eustace JA, et al. Race, mineral homeostasis and mortality in patients with end-stage renal disease on dialysis. Am J Nephrol. 2015;42(1):25–34. doi:10.1159/000438999
   PubMed Web of Science ®Google Scholar
• Sprague SM, Ketteler M, Covic AC, et al. Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018;22(4):480–491. doi:10.1111/hdi.12663
   PubMed Web of Science ®Google Scholar
• Hecking M, Bieber BA, Ethier J, et al. Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med. 2014;11(10):e1001750. doi:10.1371/journal.pmed.1001750
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Galassi A, Ciceri P. Phosphate binders in dialysis: better satisfied than sorry. Clin Kidney J. 2021;14(8):1859–1860. doi:10.1093/ckj/sfab093
   PubMed Web of Science ®Google Scholar
• Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092–2099. doi:10.1093/ndt/gft280
   PubMed Web of Science ®Google Scholar
• McCullough K, Port FK, de Sequera P, et al.; DOPPS Country Investigators. European hemodialysis patient satisfaction with phosphate binders is associated with serum phosphorus levels: the dialysis outcomes and practice patterns study. Clin Kidney J. 2021;14(8):1886–1893. doi:10.1093/ckj/sfab098
   PubMed Web of Science ®Google Scholar
• St Peter WL, Wazny LD, Weinhandl ED. Phosphate-binder use in US dialysis patients: prevalence, costs, evidence, and policies. Am J Kidney Dis. 2018;71:2. 246–253. doi:10.1053/j.ajkd.2017.09.007
   PubMed Web of Science ®Google Scholar
• US-DOPPS (Dialysis Outcomes and Practice Patterns Study) Practice Monitor. Phosphate binder use, last 3 months; 2020. Available from: https://www.dopps.org/DPM-HD/DPMSlideBrowser.aspx. Accessed October 29, 2021.
   Google Scholar
• Koiwa F, Terao A. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol. 2017;21(3):513–522. doi:10.1007/s10157-016-1299-z
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Parameswaran V, Ficociello LH, et al. Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am J Nephrol. 2018;47(3):153–161. doi:10.1159/000487856
   PubMed Web of Science ®Google Scholar
• Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K. Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis. 2014;64(1):143–150. doi:10.1053/j.ajkd.2014.01.429
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Ficociello LH, Parameswaran V, et al. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. BMC Nephrol. 2019;20(1):396. doi:10.1186/s12882-019-1582-9
   PubMed Web of Science ®Google Scholar
• Fuller DS, Xing S, Belozeroff V, et al. Variability in cinacalcet prescription across US hemodialysis facilities. Clin J Am Soc Nephrol. 2019;14(2):241–249. doi:10.2215/CJN.09550818
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Zee J, Morgenstern H, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephtrol. 2015;10(10):1814–1821. doi:10.2215/CJN.02600315
   PubMed Web of Science ®Google Scholar